Microplasmin receives orphan drug protection

Dublin-The FDA has classified a new microplasmin compound for use in pediatric vitrectomy as an orphan drug.

Related Videos
View All
Related Content

Hundreds of children to receive free eyecare, glasses

December 23rd 2022

ROP: Treating and preventing blindness in preterm babies

October 18th 2021

NovaSight introducing CureSight to U.S. market

December 16th 2022

Managing a changing landscape of IRD pediatric cases

May 10th 2021

New genetic mutation behind childhood glaucoma identified

December 5th 2022

Visual outcomes after secondary IOL implantation in aphakic children

December 1st 2022

Hundreds of children to receive free eyecare, glasses

December 23rd 2022

ROP: Treating and preventing blindness in preterm babies

October 18th 2021

NovaSight introducing CureSight to U.S. market

December 16th 2022

Managing a changing landscape of IRD pediatric cases

May 10th 2021

New genetic mutation behind childhood glaucoma identified

December 5th 2022

Visual outcomes after secondary IOL implantation in aphakic children

December 1st 2022

Hundreds of children to receive free eyecare, glasses

December 23rd 2022

ROP: Treating and preventing blindness in preterm babies

October 18th 2021

NovaSight introducing CureSight to U.S. market

December 16th 2022

Managing a changing landscape of IRD pediatric cases

May 10th 2021

New genetic mutation behind childhood glaucoma identified

December 5th 2022

Visual outcomes after secondary IOL implantation in aphakic children

December 1st 2022
Advertise
Privacy
Editorial
Terms and Conditions
Contact Us
Do Not Sell My Personal Information
Job Board
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.